基于多肽的胶质母细胞瘤治疗策略：从小分子药物到递送载体

IF 10.5 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Journal of Controlled Release Pub Date : 2025-07-10 DOI:10.1016/j.jconrel.2025.114023

Na Song , Wenmin Xiong , Jiantao Zhu , Chao Zhu , Xiangling Gu , Zhilin Yu

{"title":"基于多肽的胶质母细胞瘤治疗策略：从小分子药物到递送载体","authors":"Na Song , Wenmin Xiong , Jiantao Zhu , Chao Zhu , Xiangling Gu , Zhilin Yu","doi":"10.1016/j.jconrel.2025.114023","DOIUrl":null,"url":null,"abstract":"<div><div>Glioblastoma (GBM) remains one of the most invasive and treatment-resistant brain tumors. Efficient GBM treatment represents a significant challenge in clinical oncology, thereby underscoring the demand on novel therapeutic strategies. Peptide-based therapeutics have emerged as promising alternatives to conventional drugs, due to their precise targeting capabilities, broad bioactivities, and the prospective to overcome the blood-brain barrier (BBB). This review outlined the diverse functions of peptides in GBM treatment, ranging from targeting agents, therapeutic drugs to delivery vehicles, based on introduction of the applications of peptides towards general cancer therapy. We highlighted the advantages and potential of peptide-based therapeutics from the perspective of various targeted delivering and therapeutic strategies for GBM. While challenges related to peptide stability and bioavailability are critical for clinical usage, peptide-based therapies serving as innovative solutions hold the great potential to enhance GBM treatment efficacy and offer novel avenues for future therapeutic development.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 114023"},"PeriodicalIF":10.5000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peptide-based strategies for glioblastoma therapy: From small molecular drugs to delivery vehicles\",\"authors\":\"Na Song , Wenmin Xiong , Jiantao Zhu , Chao Zhu , Xiangling Gu , Zhilin Yu\",\"doi\":\"10.1016/j.jconrel.2025.114023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Glioblastoma (GBM) remains one of the most invasive and treatment-resistant brain tumors. Efficient GBM treatment represents a significant challenge in clinical oncology, thereby underscoring the demand on novel therapeutic strategies. Peptide-based therapeutics have emerged as promising alternatives to conventional drugs, due to their precise targeting capabilities, broad bioactivities, and the prospective to overcome the blood-brain barrier (BBB). This review outlined the diverse functions of peptides in GBM treatment, ranging from targeting agents, therapeutic drugs to delivery vehicles, based on introduction of the applications of peptides towards general cancer therapy. We highlighted the advantages and potential of peptide-based therapeutics from the perspective of various targeted delivering and therapeutic strategies for GBM. While challenges related to peptide stability and bioavailability are critical for clinical usage, peptide-based therapies serving as innovative solutions hold the great potential to enhance GBM treatment efficacy and offer novel avenues for future therapeutic development.</div></div>\",\"PeriodicalId\":15450,\"journal\":{\"name\":\"Journal of Controlled Release\",\"volume\":\"385 \",\"pages\":\"Article 114023\"},\"PeriodicalIF\":10.5000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Controlled Release\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168365925006443\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925006443","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

胶质母细胞瘤（GBM）仍然是最具侵袭性和治疗抗性的脑肿瘤之一。有效的GBM治疗是临床肿瘤学的一个重大挑战，因此强调了新的治疗策略的需求。基于肽的治疗方法由于其精确的靶向能力、广泛的生物活性和克服血脑屏障（BBB）的前景，已成为传统药物的有希望的替代品。本文在介绍多肽在一般癌症治疗中的应用的基础上，概述了多肽在GBM治疗中的多种功能，从靶向剂、治疗药物到递送载体。我们从各种靶向递送和治疗策略的角度强调了基于肽的治疗方法的优势和潜力。虽然肽稳定性和生物利用度方面的挑战对临床应用至关重要，但基于肽的疗法作为创新的解决方案，在提高GBM治疗效果方面具有巨大的潜力，并为未来的治疗发展提供了新的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Peptide-based strategies for glioblastoma therapy: From small molecular drugs to delivery vehicles

查看原文本刊更多论文

Peptide-based strategies for glioblastoma therapy: From small molecular drugs to delivery vehicles

Glioblastoma (GBM) remains one of the most invasive and treatment-resistant brain tumors. Efficient GBM treatment represents a significant challenge in clinical oncology, thereby underscoring the demand on novel therapeutic strategies. Peptide-based therapeutics have emerged as promising alternatives to conventional drugs, due to their precise targeting capabilities, broad bioactivities, and the prospective to overcome the blood-brain barrier (BBB). This review outlined the diverse functions of peptides in GBM treatment, ranging from targeting agents, therapeutic drugs to delivery vehicles, based on introduction of the applications of peptides towards general cancer therapy. We highlighted the advantages and potential of peptide-based therapeutics from the perspective of various targeted delivering and therapeutic strategies for GBM. While challenges related to peptide stability and bioavailability are critical for clinical usage, peptide-based therapies serving as innovative solutions hold the great potential to enhance GBM treatment efficacy and offer novel avenues for future therapeutic development.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.